08 jun: Colombian Stocks Decline, Led By Ecopetrol; Peso Weakens
09 jun: RBS Chairman: Issues in Restructuring Talks Include Convertible C..
08-06-2012 23:55:00

J&J to Record $600 Million Charge in 2Q

Relateret indhold
Relateret debat
01 sep - 
Dear Sir/Ma, We have direct providers of Fresh Cut BG, ..
01 sep - 
We are direct provider for BG/SBLC specifically for lea..
01 sep - 
We are direct provider for BG/SBLC specifically for lea..

Johnson & Johnson (JNJ) said it plans to record a special charge of roughly $600 million in its second quarter to increase its accrual for potential legal settlements, as it has faced a series of lawsuits over accusations of bribery and improper drug-marketing practices.

The company said the settlement payments stem for a series of outstanding civil cases that involve its drugs Risperdal, Invega and Natrecor, as well as nursing-home pharmacy operator Omnicare Inc. (OCR).

The health-care products company has faced lawsuits related to alleged off-label promotion of its antipsychotic treatment Risperdal, which was once J&J's top-selling drug before generic copycats hit the market, as well as legal challenges over off-label promotion of another schizophrenia treatment, Invega, and the heart-failure drug Natrecor.

Furthermore, the federal government is suing J&J, accusing it of paying kickbacks to induce Omnicare to encourage use of Risperdal and other J&J drugs.

In addition, J&J has dealt with state lawsuits regarding its promotion of Risperdal, including an Arkansas case in which the company in April was ordered to pay $1.2 billion after a jury found that J&J's past marketing of the drug violated the state's consumer-protection laws. J&J previously was ordered to pay $327 million in a South Carolina case and $258 million in Louisiana. The company is appealing all three cases.

In January, J&J agreed to settle a Texas case for $158 million.

Meanwhile, the company agreed to pay an $85 million fine in a criminal case regarding off-label marketing of Natrecor. Parallel civil litigation still hasn't been settled.

The company in April said its first-quarter earnings rose on a foreign-exchange-related gain tied to an acquisition and lower expenses.

Shares closed Friday at $62.98 and were unchanged after hours. The stock is down 4% so far this year.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

(END) Dow Jones Newswires

June 08, 2012 17:55 ET (21:55 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Lundbeck: Eli Lilly og Astrazeneca på vej med Alzheimers-middel

16-09-2014 16:29:37
Eli Lilly og Astrazeneca har indgået et partnerskab for at udvikle en mulig behandling til Alzheimers sygdom, fortæller medicinalvirksomhederne i en fælles medd..

Novo: Tresiba giver bedre blosukkerregulering til børn og unge

16-09-2014 12:38:17
Novo Nordisks langtidsvirkende insulinprodukt Tresiba i kombination med Novolog kan give forbedret langsigtet blodsukkerregulering hos børn og unge med type 1-d..

Aktier/middag: TDC retter sig i kedeligt marked

16-09-2014 11:43:28
De røde tal er tirsdag i klar overvægt på fondsbørsen i København, hvor mange investorer har valgt at blive på sidelinjen for at afvente onsdagens rentemøde i U..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Mærsk/Macquarie: Løfter kursmål til 20.400 kr. fra 17.600 kr.
2
Aktier/tendens: TDC i fortsat fokus på "mellemdag"
3
UK/Danske: Skotsk "ja" med mulige konsekvenser
4
Torm/fmd: Udvanding af aktionærerne forventelig
5
Novo: Tresiba giver bedre blosukkerregulering til børn og unge

Relaterede aktiekurser

Johnson & Johnson 105,88 1,1% Stigning i aktiekurs
Omnicare Inc 63,95 1,2% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Relaterede selskaber
Få adgang til information og anbefalinger af relaterede selskaber med PLUS pakken.

Du får adgang til 7 værdifulde investorværktøjer til investering.

Klik her og læs mere om PLUS pakken.
Euroinvestor i andre lande: Euroinvestor.com | Euroinvestor.se | Euroinvestor.no | Euroinvestor.fr | Forexinvestor.com| Wisselkoersen.nl | Valuta.se | Valutaveksel.no | Divisas.es | Valute.it
Copyright Euroinvestor A/S 2014  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
17. september 2014 05:32:48
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20140915.2 - EUROWEB1 - 2014-09-17 05:32:48 - 2014-09-17 05:32:48 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x